Metalyse Unión Europea - noruego - EMA (European Medicines Agency)

metalyse

boehringer ingelheim international gmbh - tenecteplase - hjerteinfarkt - antithrombotic agents - metalyse angis for thrombolytic behandling av mistenkte hjerteinfarkt med vedvarende st høyde eller siste venstre-pakke-gren blokker innen seks timer etter utbruddet av akutt-hjerteinfarkt-hjerteinfarkt symptomer.

Alburex 200 g/ L Noruega - noruego - Statens legemiddelverk

alburex 200 g/ l

csl behring gmbh - albumin, humant - infusjonsvæske, oppløsning - 200 g/ l

Alburex 50 g/ L Noruega - noruego - Statens legemiddelverk

alburex 50 g/ l

csl behring gmbh - albumin, humant - infusjonsvæske, oppløsning - 50 g/ l

Rivaroxaban Viatris (previously Rivaroxaban Mylan) Unión Europea - noruego - EMA (European Medicines Agency)

rivaroxaban viatris (previously rivaroxaban mylan)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antithrombotic agents - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Marevan 2.5 mg Noruega - noruego - Statens legemiddelverk

marevan 2.5 mg

orifarm healthcare a/s - warfarinnatrium - tablett - 2.5 mg

Xifaxan 550 mg Noruega - noruego - Statens legemiddelverk

xifaxan 550 mg

norgine bv - rifaksimin - tablett, filmdrasjert - 550 mg

Sandostatin 100 mikrog/ ml Noruega - noruego - Statens legemiddelverk

sandostatin 100 mikrog/ ml

novartis norge (2) - oktreotidacetat - injeksjons-/infusjonsvæske, oppløsning - 100 mikrog/ ml

Sandostatin 50 mikrog/ ml Noruega - noruego - Statens legemiddelverk

sandostatin 50 mikrog/ ml

novartis norge (2) - oktreotidacetat - injeksjons-/infusjonsvæske, oppløsning - 50 mikrog/ ml

Sandostatin 200 mikrog/ ml Noruega - noruego - Statens legemiddelverk

sandostatin 200 mikrog/ ml

novartis norge (2) - oktreotidacetat - injeksjons-/infusjonsvæske, oppløsning - 200 mikrog/ ml

Glypressin 1 mg Noruega - noruego - Statens legemiddelverk

glypressin 1 mg

ferring legemidler as - terlipressindiacetat - pulver og væske til injeksjonsvæske, oppløsning - 1 mg